EICHOR
● Completed
HPP737 in Adult Patients With Plaque Psoriasis
Condition: Psoriasis · Sponsor: Newsoara Biopharma Co., Ltd.
About this study
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737. The main questions it aims to answer are: Does drug HPP737 improve psoriasis severity compared to an active control drug, as measured by the proportion of patients achieving a significant reduction in the Psoriasis Area and Severity Index (PASI) score and other standardized assessments? What medical problems do participants have when taking drug HPP737? Researchers will compare drug HPP737 to an active control drug (a positive drug comparator) to see if drug HPP737 works to treat moderate-to-severe plaque psoriasis. This is a multicenter, randomized, double-blind, double-dummy, active-controlled Phase III clinical trial. Participants will: Take drug HPP737 or an active control drug orally every day Visit the clinic regularly for checkups and tests throughout the study Have their psoriasis severity assessed using standardized scoring tools, including the Psoriasis Area and Severity Index (PASI), static Physician's Global Assessment (sPGA), and Body Surface Area (BSA) The trial plans to enroll approximately 606 participants across about 61 centers in China. Eligible participants are adults aged 18 years and older with a confirmed diagnosis of stable moderate-to-severe plaque psoriasis for at least 6 months.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (60)
| Inner Mongolia Baogang Hospital | Baotou, China | — |
| Beijing Friendship Hospital, Capital Medical University | Beijing, China | — |
| Beijing Tongren Hospital, Capital Medical University | Beijing, China | — |
| Beijing Tsinghua Changgung Hospital | Beijing, China | — |
| Peking University People's Hospital | Beijing, China | — |
| Cangzhou People's Hospital | Cangzhou, China | — |
| The Second Hospital of Jilin University | Changchun, China | — |
| Changde First People's Hospital | Changde, China | — |
| Third Xiangya Hospital of Central South University | Changsha, China | — |
| The Second People's Hospital of Changzhi | Changzhi, China | — |
| Affiliated Hospital of Chengde Medical College | Chengde, China | — |
| Chengdu Second People's Hospital | Chengdu, China | — |
+ 48 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07712731